Yahoo Malaysia Web Search

Sign In

Search results

  1. uk.advfn.com › stock-market › AMEXForm 424B2 - Prospectus [Rule 424(b)(2)] - ADVFN

    1 day ago · Options Flow. Explore comprehensive options data and use advanced filters with Options Flow.

  2. www.wallstreet-online.de › nachricht › 18149531-evoke-01-studyEVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an...

    1 day ago · 31.05.2024 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #LBA8500) today (2:45-5 ...

  3. www.wallstreet-online.de › nachricht › 18149438-pfizer-sPfizer’s LORBRENA CROWN Study Shows Majority of Patients with ALK...

    1 day ago · Nausea (56%), decreased appetite (30%), fatigue (29%), and neuropathy (21%) also occurred in patients taking XALKORI. Drug Interactions: Use caution with concomitant use of moderate CYP3A inhibitors.

  4. www.finanzen.ch › nachrichten › aktienPfizer’s LORBRENA® CROWN Study Shows Majority of Patients with...

    1 day ago · Nausea (56%), decreased appetite (30%), fatigue (29%), and neuropathy (21%) also occurred in patients taking XALKORI. Drug Interactions: Use caution with concomitant use of moderate CYP3A inhibitors.

  5. script.finanzen.ch › nachrichten › aktienPfizer’s LORBRENA® CROWN Study Shows Majority of Patients with...

    1 day ago · Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-gener...

  6. www.placera.se › placera › pressmeddelandenEVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an...

    1 day ago · Newly diagnosed patients have several treatment options including platinum-based therapy, checkpoint inhibitors and targeted therapies. However, there are limited treatment options once patients with metastatic NSCLC progress on or after platinum-based chemotherapy and checkpoint inhibitors. About the EVOKE-01 Study